tyrosine-kinase inhibitor

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

tyrosine-kinase inhibitor

Sep 2, 2024, 03:41 | Insight

FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC

The FDA has recently granted Zongertinib, a HER2-specific tyrosine kinase inhibitor (TKI), Breakthrough Therapy Designation…

Apr 14, 2024, 22:26 | Insight

Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn:…

Apr 12, 2024, 10:05 | Drugs

Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure

Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…

All: 3 Posts: 1 - 100